Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations

JAMA

Volumn 283, Issue 5, 2000, Pages 617-624

  Schrag, Deborah ^a,b,d   Kuntz, Karen M ^c   Garber, Judy E ^a   Weeks, Jane C ^a  

^a Department of Adult Oncology ^*  (United States)

^b Center for Outcomes and Policy Research   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; GENE MUTATION; LIFE EXPECTANCY; MASTECTOMY; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; PROBABILITY; SECOND CANCER;

EID: 0034594659     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.5.617     Document Type: Article

References (59)

1. Easton DF, Ford D, Bishop DT, for the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet. 1995;56:265-271.
2. Ford D, Easton DF, Stratton M, et al, for the Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62: 676-689.
3. Broet P, de la Rochefordiere A, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol. 1995;13:1578-1583.
4. Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol. 1993; 11:1545-1552.
5. Rosen PP, Groshen S, Kinne DW, Hellman S. Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1NOMO) and stage II (T1N1MO) patients with 20-year follow-up. Surgery. 1989;106: 904-910.
6. Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol. 1991;9:1650-1661.
7. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998 [published corrections appear in CA Cancer J Clin. 1998;48:192 and CA Cancer J Clin. 1998;48:329] . CA Cancer J Clin. 1998;48:6-29.
8. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998 [published corrections appear in CA Cancer J Clin. 1998;48:192 and CA Cancer J Clin. 1998;48:329] . CA Cancer J Clin. 1998;48:6-29.
9. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998 [published corrections appear in CA Cancer J Clin. 1998;48:192 and CA Cancer J Clin. 1998;48:329] . CA Cancer J Clin. 1998;48:6-29.
10. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999; 340:77-84.
11. Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr. 1995;17:33-35.
12. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
13. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis: effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997; 336:1465-1471.
14. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol. 1998;16:979-985.
15. Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes; a decision analysis. Med Decis Making. 1998;18:365-375.
16. Ventura SJ, Anderson RN, Martin JA, Smith BL. Births and deaths: preliminary data for 1997. Natl Vital Stat Rep. 1998;47:1-41.
17. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998;351:316-321.
18. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol. 1998;16:397-404.
19. Lee JS, Wacholder S, Struewing JP, et al. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 1999; 91:259-263.
20. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930-942.
21. Chu KC, Tarone RE, Kessler LG, et al. Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst. 1996;88:1571-1579.
22. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer. 1998;82: 1197-1207.
23. Smart CR, Byrne C, Smith RA, et al. Twenty-year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project. CA Cancer J Clin. 1997;47:134-149.
24. Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol. 1998;16:1642-1649.
25. Fodor FH, Weston A, Bleiweiss IJ, et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet. 1998;63:45-51.
26. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14: 185-187.
27. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998;352:1337-1339.
28. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
29. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997;60:496-504.
30. Burke W, Daly M, Garber J, et al, for the Cancer Genetics Studies Consortium. Recommendations for follow-up care of individuals with an inherited predisposition to cancer, II: BRCA1 and BRCA2. JAMA. 1997;277:997-1003.
31. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997;349:1505-1510.
32. DePriest PD, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell JR Jr. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol. 1997;65:408-414.
33. US Surveillance and Epidemiology End Results Program. SEER Public Use Data 1973-1994. Bethesda, Md: National Cancer Institute, Cancer Statistics Branch; 1996.
34. Ries LA. Ovarian cancer: survival and treatment differences by age. Cancer. 1993;71(2 suppl):524-529.
35. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 1996;335:1413-1416.
36. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333:1456-1461.
37. Bandera CA, Muto MG, Schorge JO, Berkowitz RS, Rubin SC, Mok SC. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol. 1998;92(4 pt 1):596-600.
38. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet. 1993;341:1293-1298.
39. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 1996;348:1189-1196.
40. Rivkin SE, Green S, O'Sullivan J, et al. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1996;14:46-51.
41. Schairer C, Persson I, Falkeborn M, Naessen T, Troisi R, Brinton LA. Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer. 1997;70:150-154.
42. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999; 91:1475-1479.
43. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110.
44. DiSaia PJ, Grosen EA, Odicino F, et al. Replacement therapy for breast cancer survivors: a pilot study. Cancer. 1995;76(10 suppl):2075-2078.
45. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
46. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996; 347:714-718.
47. Cooper GS, Sandler DP. Age at natural menopause and mortality. Ann Epidemiol. 1998;8:229-235.
48. Colditz GA. Estrogen replacement therapy for breast cancer patients. Oncology (Huntingt). 1997; 11:1491-1494.
49. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA. 1996;275:1885-1892.
50. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer: a decision-analysis model. N Engl J Med 1991;324:160-168.
51. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med. 1998:339:380-386.
52. Lindfors KK, Rosenquist CJ. The cost-effectiveness of mammographic screening strategies [published correction appears in JAMA. 1996;275. 112]. JAMA. 1995;274:881-884.
53. Lindfors KK, Rosenquist CJ. The cost-effectiveness of mammographic screening strategies [published correction appears in JAMA. 1996;275. 112]. JAMA. 1995;274:881-884.
54. Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications [published correction appears in Circulation. 1991; 84:2610]. Circulation. 1991;83:1194-1201.
55. Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications [published correction appears in Circulation. 1991; 84:2610]. Circulation. 1991;83:1194-1201.
56. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
57. Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer. 1997;33:362-371.
58. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999;130:431-439.
59. Narod SA, Risch H, Moslehi R, et al, for the Hereditary Ovarian Cancer Clinical Study Group. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 1998;339:424-428.